Chlamydia trachomatis and anti-MUC1 antibodies and subsequent risk of high grade serous ovarian cancer; a population-based case-control study in Northern Sweden.

• Main Author: Ottander, Ulrika
• Format: Other/Unknown Material
• Language: English
• Published: Morressier 2017
• Subjects: demo; socio; Northern Sweden
• Online Access: https://doi.org/10.26226/morressier.5d43ffa5baa7e4c58300ac94; https://openresearchlibrary.org/ext/api/media/f5085045-c005-46db-afd2-4a02512abd08/assets/external_content.pdf; https://openresearchlibrary.org/viewer/f5085045-c005-46db-afd2-4a02512abd08

Background:Chlamydia trachomatis (C. trachomatis) salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting anti-MUC1 antibody levels. The aim of this study was to examine if serology indicating past infection with C. trachomatis as well as anti-MUC1 production was associated with subsequent risk of HGSC. Material and methods:In a prospective nested case-control study within the Northern Sweden Health and Disease Study (NSHDS) and the Northern Sweden Maternity Cohort (NSMC), the prevalence of chlamydial and anti-MUC1 antibodies was analyzed in blood samples drawn more than one year prior to diagnosis from 92 women with HGSC and 359 matched controls. Matching factors were age, date at blood draw and sampling cohort. Plasma C. trachomatis IgG was analyzed using commercial MIF-test; chlamydial Heat Shock Protein 60 IgG (cHSP60) and anti-MUC1 IgG were analyzed with ELISA technique. Results:The prevalence of C. trachomatis IgG and cHSP60 IgG antibodies, as well as the level of anti-MUC1 IgG was similar in women with HGSC and controls (16.3% vs. 17.0%, p = 0.867; 27.3% vs 28.5%, p = 0.802; median 0.24 vs 0.25, p = 0.700). Anti-MUC1 IgG and cHSP60 IgG levels were correlated (r = 0.169; p <0.001).Conclusions:The findings of this prospective nested case control study did not support an association between C. trachomatis infection, as measured by chlamydial serology, or anti-MUC1 IgG antibodies, and subsequent risk of HGSC.